Trial Profile

A Phase 1 Sequential Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of CAL-101 in Patients With Select, Relapsed or Refractory Hematologic Malignancies.

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 19 Sep 2016

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Idelalisib (Primary)
Indications Acute myeloid leukaemia; B-cell lymphoma; Chronic lymphocytic leukaemia; Mantle-cell lymphoma; Multiple myeloma; Non-Hodgkin's lymphoma
Focus Adverse reactions
Sponsors Gilead Sciences

08 Dec 2015 Results of post-hoc analysis (n=494) of this and other three trial (see profile 59751, 54699 and 214177) were presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
08 Dec 2015 Results of a pooled post hoc analysis presented at the 57th Annual Meeting and Exposition of the American Society of Hematology.
08 Dec 2015 Post hoc results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com